Market Place
Sourcing Support
Rhythm And Axovia Announce Collaboration In Bardet-Biedl Syndrome
24 Oct 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Q3 2024 Financial Results on November 5
23 Oct 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
09 Oct 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
08 Oct 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
16 Sep 2024 //
GLOBENEWSWIRE
Rhythm Pharma to Present at Wells Fargo Healthcare Conference in September
26 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharma Announces FDA Priority Review for IMCIVREE® for Patients Aged 2+
26 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals To Present At Wells Fargo Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
FDA Accepts Rhythm`s sNDA For IMCIVREE In Patients As Young As 2 Years Old
26 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
13 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Reports Q2 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharma`s IMCIVREE® Approved For Children 2+ In Europe
31 Jul 2024 //
GLOBENEWSWIRE
Rhythm To Report Q2 2024 Results On August 6
23 Jul 2024 //
GLOBENEWSWIRE
Rhythm Doses First Patients In Phase 2 Trial Of LB54640
23 Jul 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11 Jul 2024 //
GLOBENEWSWIRE
Rhythm Pharma Names Alastair Garfield, Ph.D., As Chief Scientific Officer
08 Jul 2024 //
GLOBENEWSWIRE
Rhythm Pharma Receives Positive CHMP Opinion For IMCIVREE In Young Children
28 Jun 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11 Jun 2024 //
GLOBENEWSWIRE
Rhythm`s Hypothalamic Obesity Hyperphagia Patient Experience At ENDO
03 Jun 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
03 Jun 2024 //
GLOBENEWSWIRE
Anti-Obesity Drugs Market Report On Major Pharma Players
31 May 2024 //
BUSINESSWIRE
Rhythm Gets NICE Positive Recommendation For Imcivree In Bardet-Biedl
22 May 2024 //
GLOBENEWSWIRE
NICE recommends Rhythm’s Imcivree for rare genetic obesity disorder
22 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
09 May 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Q1 2024 Results And Business Update
07 May 2024 //
GLOBENEWSWIRE
Rhythm Presents Pediatric Phase 3 Data At Endo Society Meeting
06 May 2024 //
GLOBENEWSWIRE
Rhythm: Setmelanotide Phase 2 Hypothalamic Obesity Data in Lancet
29 Apr 2024 //
GLOBENEWSWIRE
Rhythm Pharma to Report Q1 2024 Results on May 7
24 Apr 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
16 Apr 2024 //
GLOBENEWSWIRE
Rhythm Secures $150 Million in Convertible Preferred Stock Financing
01 Apr 2024 //
GLOBENEWSWIRE
Rhythm Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718
25 Mar 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11 Mar 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
06 Mar 2024 //
GLOBENEWSWIRE
Rhythm Reports Fourth Quarter 2023 Financial Results and Business Update
22 Feb 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide
22 Feb 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
08 Feb 2024 //
GLOBENEWSWIRE
Rhythm Pharma Announces Positive Reimbursement Decision in Italy for IMCIVREE
07 Feb 2024 //
GLOBENEWSWIRE
Rhythm to Report Fourth Quarter and Full Year 2023 Financial Results
31 Jan 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
12 Jan 2024 //
GLOBENEWSWIRE
Rhythm Announces Completion of Screening for Enrollment in Setmelanotide Trial
04 Jan 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement
04 Jan 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
15 Dec 2023 //
GLOBENEWSWIRE
Rhythm Sponsors Second Annual Meeting on Pathway-Related Obesity
13 Dec 2023 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
06 Dec 2023 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
13 Nov 2023 //
GLOBENEWSWIRE
Rhythm Reports Third Quarter 2023 Financial Results and Business Update
07 Nov 2023 //
GLOBENEWSWIRE
Rhythm Receives Positive CADTH Reimbursement Recommendation for IMCIVREE
02 Nov 2023 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results
25 Oct 2023 //
GLOBENEWSWIRE
Rhythm Presents Data from its Long-term Extension Study of Setmelanotide
17 Oct 2023 //
GLOBENEWSWIRE
Rhythm’s drug shows 25% drop in BMI over one year for patients
17 Oct 2023 //
ENDPTS
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
13 Oct 2023 //
GLOBENEWSWIRE
Rhythm Announces Abstracts to be Presented at Obesity Society™s Annual Meeting
10 Oct 2023 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
22 Sep 2023 //
GLOBENEWSWIRE
Rhythm Receives Orphan Drug Designation from EMA for Setmelanotide
19 Sep 2023 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces Update to September Conference Participation
08 Sep 2023 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
08 Sep 2023 //
GLOBENEWSWIRE
Rhythm Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
06 Sep 2023 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals to Present at Investor Conferences in September
28 Aug 2023 //
GLOBENEWSWIRE
Rhythm Announces Pre-Marketing Early Access Authorization for Setmelanotide
07 Aug 2023 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
04 Aug 2023 //
GLOBENEWSWIRE
